Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb 12;2010(34):611-616.
doi: 10.1039/b9nj00787c.

Effect of Peptide-Chelate Architecture on Metabolic Stability of Peptide-based MRI Contrast Agents

Zhaoda Zhang  1 , Andrew F Kolodziej, Jianfeng Qi, Shrikumar A Nair, Xifang Wang, April W Case, Matthew T Greenfield, Philip B Graham, Thomas J McMurry, Peter Caravan
Affiliations

Effect of Peptide-Chelate Architecture on Metabolic Stability of Peptide-based MRI Contrast Agents

Zhaoda Zhang et al. New J Chem. .

Abstract

A strategy for preparing high relaxivity, metabolically stable peptide-based MR contrast agents is described.

PubMed Disclaimer

Figures

Figure 1
Figure 1
NMRD showing field- and medium-dependent relaxivity of 5 at 35 °C in TBS buffer (open triangles), 30 μM human fibringogen/TBS (open circles), human plasma (filled triangles), and 30 μM fibrin gel (filled circles). NMRD of [Gd(DTPA)]2− in plasma (filled squares) shown for reference.
Figure 2
Figure 2
T1-weighted MR images of 5 in unclotted (A) and clotted (B) human plasma from a 1.5T clinical scanner (General Electric) with a 6 cm surface coil, using a spoiled gradient echo sequence (TE/TR/α: 3/39/40°)
Figure 3
Figure 3
Relaxometric analysis of 5: A) VT O-17 NMR (1/T1 open squares, 1/T2 filled squares) at 7.05T in TBS. VT NMRD in TBS (B) and fibrin gel (C) at 5° (open circles), 15° (filled circles), 25° (open triangles), and 35°C (filled triangles\). Solid lines are fits to data.
Scheme 1
Scheme 1
Compounds used in this study.
See this image and copyright information in PMC

References

    1. Kim YS, He Z, Hsieh WY, Liu S. Bioconjug Chem. 2007;18:929–936. - PMC - PubMed
    1. Liu S. Chem Soc Rev. 2004;33:445–461. - PubMed
    1. Caravan P. Acc Chem Res. 2009;42:851–862. - PubMed
    1. Adessi C, Soto C. Curr Med Chem. 2002;9:963–978. - PubMed
    1. Sawyer TK. In: Peptide-Based Drug Design. Taylor MD, Amidon GL, editors. American Chemical Society; Washington: 1995. p. 387.

LinkOut - more resources